Business Context and Reporting Period
This Form 8-K was filed by Ginkgo Bioworks Holdings, Inc. on February 26, 2026, reporting a material definitive agreement entered into on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the terms of a strategic transaction rather than periodic financial performance.
Material Changes
The primary material change is the entry into a Stock Purchase Agreement with Tower Biosecurity, Inc. Key terms include:
- Asset Transfer: Ginkgo Bioworks, Inc. (a wholly owned subsidiary) will contribute all equity interests of Ginkgo Biosecurity, LLC to Tower Biosecurity, Inc.
- Scope: The transaction involves substantially all operations comprising the Company's Biosecurity segment.
- Consideration: In exchange, the Company will receive shares of Tower Biosecurity, Inc. common stock representing approximately 20% of the Purchaser's issued and outstanding equity on a fully diluted basis.
- Timeline: Completion is expected in the first half of 2026, subject to customary closing conditions.
Outlook, Risks, and Contingencies
Management commentary is limited to the transaction mechanics and standard forward-looking statement disclaimers. Significant risks and contingencies identified include:
- Failure to consummate the transaction in a timely manner or at all.
- Non-satisfaction or non-waiver of closing conditions.
- Potential delays in closing.
- Events or circumstances that could trigger termination of the Purchase Agreement.
The Company explicitly states it assumes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the full text of the Stock Purchase Agreement (Exhibit 1.1) for specific closing conditions and termination rights.
- Confirm the financial impact of divesting the Biosecurity segment on future consolidated revenue and earnings.
- Assess the valuation and liquidity of the 20% equity stake to be received in Tower Biosecurity, Inc.
- Monitor regulatory approvals required to close the transaction in the first half of 2026.